Trials / Completed
CompletedNCT01224028
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
Double-blind, Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor, Tacrolimus(Prograf Cap®) in Patients With Non-nephrotic Albuminuric, Normotensive IgA Nephropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tacrolimus | oral |
| DRUG | Placebo | oral |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2010-10-19
- Last updated
- 2014-08-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01224028. Inclusion in this directory is not an endorsement.